CTNM today
$10.52-$0.25 (-2.32%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourSymmetric Triangle
1 hourStrong Bullish
15 minBearish
5 minSymmetric Triangle
Daily trend turns up above $17.79
Key levels
Resistance$12.43
Resistance$11.37
Support$10.32
Support$8.59
About Contineum Therapeutics
Contineum Therapeutics is a drug developer focused on treatments for brain, immune and inflammatory disorders. Its main experimental medicine, PIPE-791, blocks the LPA1 receptor and is in testing for lung scarring disease and persistent pain. A partner at Johnson & Johnson is running trials of a second compound, PIPE-307, for depression and multiple sclerosis. The company is based in the United States and keeps global rights to its LPA1 receptor programs.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
Contineum Therapeutics, Inc. (CTNM)
What Is the Price Target for CTNM?
SEPT Low Target
$14.00
SEPT Mid Target
$20.00
SEPT High Target
$30.00
Analyst Consensus
$20.00
Is CTNM a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CTNM.
Start Free Trial →Is CTNM Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$19.11
12
Moat Score
NONE
3/9
Piotroski Score
9.6
Altman Z-Score
What Is Smart Money Doing with CTNM?
Insider Signal
SELLING
0 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Stengone Carmine N. | director officer | Buy | 2,500 | $3K | Sep 8, 2026 |
| Stengone Carmine N. | director officer | Sale | 2,500 | $41K | Sep 8, 2026 |
| Lorrain Daniel S. | officer | Sale | 4,170 | $55K | Jun 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CTNM Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
0.46%
FCF Growth YoY
-66.5%
Revenue Trend
UNKNOWN
Dark Pool Trades for CTNM
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CTNM, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:37:21 | $10.68 | 4,906 | $$52K | BUY |
| 15:34:26 | $10.60 | 3,732 | $$40K | SELL |
| 15:14:35 | $10.64 | 1,604 | $$17K | MIDPOINT |
| 14:56:15 | $10.80 | 4,513 | $$49K | MIDPOINT |
| 14:56:15 | $10.87 | 1,000 | $$11K | BUY |
5 dark pool trades shown · $$169K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Contineum Therapeutics, Inc. (CTNM) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CTNM — frequently asked questions
What is CTNM stock price today?
Contineum Therapeutics, Inc. (CTNM) is at $10.52, down 2.32% (-$0.25) at the Nov 12, 2026 close.
Why is CTNM stock moving today?
Latest CTNM news — Nov 3, 2026: Contineum Therapeutics Posts Q3 2026 Financials
What is the CTNM price target?
The average analyst price target for CTNM is $20.00, ranging from $14 to $30, based on 4 analysts. Latest: Jones Trading maintains on Oct 15, 2026.
What do analysts rate CTNM?
Analyst ratings for CTNM: 0 Buy, 5 Hold, 1 Sell — consensus Hold.
Did CTNM beat earnings?
CTNM last reported on Nov 3, 2026: EPS -$0.49 vs -$0.45 expected — a miss of 8.9%.
Does CTNM pay a dividend?
CTNM does not currently pay a dividend.
What are CTNM support and resistance levels?
Support: $10.32, $8.59, $6.72. Resistance: $11.37, $12.43, $13.86.
What are insiders doing with CTNM?
Insider activity: SELLING, 0 buys and 13 sells in the last 90 days.
What is the latest news on CTNM?
Nov 3, 2026: Contineum Therapeutics Posts Q3 2026 Financials